As such, addressing immunotherapy resistance in MSS CRC remains a major challenge, with ongoing research into innovative strategies to enhance immune activation, including TGF-β blockade, microbiome modulation, and combination therapies. Here, TGFB1 is linked to colorectal carcinoma.